Annual report pursuant to Section 13 and 15(d)

Subsequent Events

Subsequent Events	12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	(17) Subsequent Events Extraordinary General Meeting of Shareholders On January 30, 2024, the Company asked its shareholders to renew the disapplication of statutory pre-emption rights over 5,000,000 authorized but unissued ordinary shares at an extraordinary general meeting of shareholders. Although the Company received over 53% support of the votes cast on renewing the disapplication of statutory pre-emption rights at the EGM, the Company did not receive the affirmative vote of at least 75% of the votes cast as required under Irish law for the passing of special resolutions. Data readout - Phase 3 clinical trial for oral sulopenem for the treatment of uncomplicated urinary tract infections In January 2024, the Company announced that sulopenem met the primary endpoint of statistical non-inferiority to Augmentin® in the Augmentin®-susceptible population, and demonstrated statistically significant superiority versus Augmentin® in the Augmentin® susceptible population, in the REASSURE clinical trial. Equity Offerings Subsequent to December 31, 2023, through February 29, 2024, the Company sold 2.9 million ordinary shares under the “at-the-market” agreement, with HC Wainwright as agent, at an average price of $2.52 per share for net proceeds of $7.1 million.

Subsequent Events

12 Months Ended

Dec. 31, 2023

(17) Subsequent Events

Extraordinary General Meeting of Shareholders

On January 30, 2024, the Company asked its shareholders to renew the disapplication of statutory pre-emption rights over 5,000,000 authorized but unissued ordinary shares at an extraordinary general meeting of shareholders. Although the Company received over 53% support of the votes cast on renewing the disapplication of statutory pre-emption rights at the EGM, the Company did not receive the affirmative vote of at least 75% of the votes cast as required under Irish law for the passing of special resolutions.

Data readout - Phase 3 clinical trial for oral sulopenem for the treatment of uncomplicated urinary tract infections

In January 2024, the Company announced that sulopenem met the primary endpoint of statistical non-inferiority to Augmentin® in the Augmentin®-susceptible population, and demonstrated statistically significant superiority versus Augmentin® in the Augmentin® susceptible population, in the REASSURE clinical trial.

Equity Offerings

Subsequent to December 31, 2023, through February 29, 2024, the Company sold 2.9 million ordinary shares under the “at-the-market” agreement, with HC Wainwright as agent, at an average price of $2.52 per share for net proceeds of $7.1 million.